Skip to content
etf.net

Launched · SEC filings

Franklin Genomic Advancements ETF

HELXCboeFranklin TempletonC

$43.38−0.70 (−1.59%)

As of Nov 10, 2026, 11:25 AM ET

C39/ 100

Rank 13 of 17 in Biotech & Genomics

C39/100Rank 13 of 17inBiotech & Genomics
Intraday session: down, 24 prints from 44.08 to 43.38. Range 43.36 to 44.08. Use the arrow keys to read each point.43.6043.8010 AM12 PM2 PM4 PM
Expense ratio
0.50%
Fund size
$34M
1Y total return
+28.7%
Yield · Last 12 months
0.33%
Holdings
68
Avg volume · 30D
5.25K sh
52W range
low $31.24high $46.22
Launched
Filings
SEC EDGAR

The ETF.net HELX Grade

Based on 5 of 6 pillars

C

Score 39 out of 100

Category
Biotech & Genomics⁠
Rank
13 of 17
Six-pillar profile for HELX. Scores out of 100: Cost 38, Risk 36, Mission not scored, Tradability 34, Holdings 61, Durability 43. Strongest: Holdings (61). Weakest: Tradability (34). Based on 5 of 6 pillars.

Score 39 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25. The letter stays C for now. A new letter must hold for 3 published runs before it replaces it.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    D38 out of 100
    Rank 10 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    D36 out of 100
    Rank 12 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D34 out of 100
    Rank 11 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    B61 out of 100
    Rank 9 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    C43 out of 100
    Rank 12 of 17

Our read on HELX

ETF.net Research

In short

CMost genomics funds hand you an index. Franklin's take is a stock-picker's portfolio of roughly 60 global names tied to gene sequencing, gene therapy and precision medicine, launched in 2020 with a plain mandate: capital appreciation.

Stated mandate

The Fund seeks capital appreciation.

Why people hold it

  • A concentrated bet, not a basket: about 60 global holdings across the genomics chain, so individual breakthroughs actually move the fund instead of being diluted by hundreds of names.
  • Global by design. The mandate is not fenced to US listings, which matters in a field where sequencing and gene-therapy leaders sit in Europe and Asia too.
  • Fee sits right at the middle of the genomics and biotech peer group at 0.50%, so you are not paying a premium over the typical thematic competitor for a discretionary approach.
  • Live since 2020, giving it a multi-year record through a brutal stretch for biotech, rather than a launch-window track record.

Worth knowing

  • It is a small, thinly traded fund. Use limit orders, expect wider spreads than the big index names, and know that small ETFs carry more closure risk than entrenched ones.
  • The low-cost, high-liquidity lane in this category belongs to index products like IBBQ (0.19%) and IBB (0.44%). HELX's case rests on the manager's picks, not on price or trading ease.
  • Genomics is a growth-style, high-volatility corner of health care. Clinical trial results and rate moves can swing a 60-stock portfolio hard in both directions.

HELX Holdings

Holdings pillarB61 out of 100Rank 9 of 17 in Biotech & Genomics
Asset class
Stocks
Holdings
68
Top-10 weight
46%
Largest holding
GH8.7%

Sectors

  • Health Care96.8%
  • Financials2.2%
  • Technology0.7%
  • Materials0.4%

Geography

  • United States95.31%
  • South Korea1.07%
  • United Kingdom1.02%
  • Germany0.93%
  • Denmark0.84%
  • Switzerland0.83%
The fund’s holdings, weight-ordered — page 1 of 5.
#TickerCompanyWeight %SharesMarket valueHeld by ETFs
1GHGuardant Health Inc8.65%19,345$2.92M182
2NTRANatera Inc8.08%8,775$2.73M241
3ADPTAdaptive Biotechnologies4.92%59,378$1.66M88
4KRYSKrystal Biotech Inc4.85%5,435$1.64M157
5LGNDLigand Pharmaceuticals4.61%5,085$1.56M138
6TWSTTwist Bioscience Corp3.46%9,673$1.17M128
7BBIOBridgebio Pharma Inc3.30%15,003$1.11M123
8MEDPMedpace Holdings Inc2.92%1,509$986K217
9VRTXVertex Pharmaceuticals In2.86%1,765$966K433
10LLYEli Lilly & Co2.75%685$927K596
11UTHRUnited Therapeutics Corp2.72%1,634$918K276
12REGNRegeneron Pharmaceuticals2.46%919$831K428
13TVTXTravere Therapeutics Inc2.38%16,163$802K111
14VYLRVylor Inc2.17%10,453$733K248
15CDNACaredx Inc2.13%9,142$718K116

Showing 1–15 of 68 holdings

HELX Performance

Launched Feb 25, 2020

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.
HELX$12,868
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,339
Nov 7, 2025 to Nov 9, 2026. HELX $12,868. SPY $11,339. Use the arrow keys to read each point.$10,000$12,000Nov 2025May 2026Nov 2026

Nov 7, 2025 – Nov 9, 2026

Returns run to the Nov 9, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for HELX. Periods over one year show the average yearly return.
PeriodHELX
Year to date+21.4%
1 month+3.4%
3 months+6.7%
1 year+28.7%
3 yearsper year+19.3%
5 yearsper year−2.6%
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for HELX
YearReturn barHELX
2026 YTD+21.4%
2025+26.4%

HELX in the news

HELX Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Nov 9, 2026.
0.33%Last 12 months
Payout per share
$0.14Last 12 months
Last payment
$0.14 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Irregular

Distribution history

2023–2026

One bar per payment. 1 payment from 2023 to 2026 YTD. Dec 30, 2025 $0.14. Use the arrow keys to read each point.2023202420252026YTD
Ex-datePay dateAmount per share
Dec 30, 2025Jan 8, 2026$0.14
Dec 30, 2021Jan 7, 2022$0.0039
Dec 13, 2021Dec 21, 2021$0.11
Dec 14, 2020Dec 23, 2020$0.05

$10,000 in HELX 5 years ago paid $51.96 in dividends.

HELX Risk

Risk pillarD36 out of 100Rank 12 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
20.8%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.82
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−52.9%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.98
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

HELX Cost

Compare HELX and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$6,027

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • HELX 0.50%

    $9,979

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • HELX 0.50%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K$10K051015202530HELX $9,979IBBQ $3,952

Year by year

YearHELXIBBQOverpaying
10$900$347$553
20$3,460$1,351$2,109
30$9,979$3,952$6,027

Other funds in Biotech & Genomics

See others